Boceprevir: interaction with HIV protease inhibitors highlighted

The European Medicines Agency (EMA) has recommended that patients receiving concomitant therapy with the hepatitis C protease inhibitor boceprevir (Victrelis) and HIV protease inhibitors be reviewed for potential virologic rebound, following reports of a pharmacokinetic interaction.

Victrelis was the first protease inhibitor to be launched in the UK for hepatitis C
Victrelis was the first protease inhibitor to be launched in the UK for hepatitis C

Pharmacokinetic study

A study in 39 healthy volunteers showed that blood levels of three ritonavir-boosted protease inhibitors (darunavir, lopinavir and atazanavir) were markedly reduced when given with boceprevir. In addition, levels of boceprevir were reduced when given with ritonavir-boosted darunavir or lopinavir, although this effect was not seen with ritonavir–atazanavir.

Recommendations

The EMA states that co-administration of boceprevir with ritonavir-boosted darunavir or lopinavir is not recommended. Co-administration of atazanavir–ritonavir with boceprevir may be considered on a case-by-case basis in patients with suppressed HIV viral loads and without any suspected resistance to the HIV regimen. Increased clinical and laboratory monitoring is recommended in this situation.

Licensed indication

Victrelis is indicated for the treatment of chronic hepatitis C genotype 1, in combination with peginterferon alfa and ribavirin. The safety and efficacy of Victrelis in HIV co-infected patients has not been established.

View Victrelis drug record

Further information: Merck Sharp & Dohme Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New once-weekly GLP-1 agonist for diabetes

New once-weekly GLP-1 agonist for diabetes

Ozempic (semaglutide) is a glucagon-like peptide-1...

Gluten-free prescribing restricted to bread and mixes

Gluten-free prescribing restricted to bread and mixes

GPs in England are no longer able to prescribe gluten-free...

New vitamin D deficiency thresholds recommended

New vitamin D deficiency thresholds recommended

The National Osteoporosis Society (NOS) has updated...

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors may be linked to a doubling in the...